Albumin News and Research

RSS

Study identifies risk factors for vitamin D deficiency in kidney disease patients on dialysis

Vitamin D deficiency is almost universal among kidney disease patients who have low blood protein levels and who start dialysis during the winter, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The research identifies a group of patients who are at extremely high risk of being deficient in vitamin D and provides some clues as to why the deficiency occurs in these individuals.

26 Feb 2010

Revisional bariatric surgery linked to higher risk of complications

Revisional bariatric surgery appears to be associated with a higher risk of complications than the initial procedure, according to a report in the February issue of Archives of Surgery, one of the JAMA/Archives journals.

16 Feb 2010

ConjuChem Biotechnologies reports financial results for fiscal year ended October 31, 2009

The Company's net loss for the quarter ended October 31, 2009 amounted to $2.5 million or ($0.01) per share, compared to $10.9 million or ($0.04) per share, for the quarter ended October 31, 2008.

29 Jan 2010

SCI indicates increased risk of declining kidney function in type 2 diabetics

In patients with type 2 diabetes, silent cerebral infarction (SCI)—small areas of brain damage caused by injury to small blood vessels—signals an increased risk of progressive kidney disease and kidney failure, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

29 Jan 2010

Baxter International reports net income of $572M for the fourth-quarter of 2009

Baxter International Inc. today reported strong performance for the fourth quarter of 2009, and provided its financial outlook for the first quarter and full-year 2010.

From Baxter International Inc. 28 Jan 2010

Neomend completes $30M Series D funding round

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced today it has completed a funding round of $30 million, with Clarus Ventures, LLC investing $17 million.

28 Jan 2010

Neomend receives premarket approval from FDA for ProGEL Pleural Air Leak Sealant

Neomend, Inc., an innovator in sealant and adhesion-prevention products for the surgical marketplace, announced it has received premarket approval from the U.S. Food and Drug Administration (FDA) for the company’s ProGEL™ Pleural Air Leak Sealant.

20 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Amylin Pharmaceuticals' modified exendins and exendin agonists patent: USPTO issues Final Office Action

ConjuChem Biotechnologies Inc. announced today that the U.S. Patent & Trademark Office (USPTO) has issued a Right of Appeal Notice (Final Office Action) in the inter partes reexamination of Patent No. 6,924,264. The patent, entitled "Modified Exendins and Exendin Agonists," was issued in August 2005 and is assigned to Amylin Pharmaceuticals, Inc. The Action once again rejected all the subject claims for obviousness and/or lack of novelty. The inter partes reexamination in the USPTO does not involve any of ConjuChem's patents.

22 Dec 2009

Multiple clinical study results of ABRAXANE to be presented by Abraxis BioScience

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that multiple clinical studies of the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS), being held in San Antonio, Texas from December 9 to December 13.

9 Dec 2009

New tool may allow doctors to predict long-term survival rates of dialysis patients

A new model can help physicians determine if a kidney disease patient on dialysis is likely to die within the next few months, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

4 Dec 2009

FDA approves additional intended use of Roche's cobas TaqScreen MPX Test

Roche announced today that the United States Food & Drug Administration (FDA) approved an additional intended use for its licensed nucleic acid test, to screen source plasma in pools comprised of up to 96 individual donations. The test, called the cobas® TaqScreen MPX Test for use on the cobas s 201 system, is a qualitative, in-vitro test for the simultaneous, direct detection of the human immunodeficiency virus (HIV-1 Group M RNA, HIV-1 Group O RNA , HIV-2 RNA), hepatitis C virus RNA and hepatitis B virus DNA in human plasma.

From Roche Sequencing and Life Science 2 Dec 2009

Canadians with hemophilia A can use new treatment option, XYNTHA

Canadians with hemophilia A - a rare, inherited blood-clotting disorder - now have a new treatment option with the introduction of XYNTHA(TM), a recombinant factor VIII product for both the control and prevention of bleeding episodes and surgical prophylaxis.

2 Dec 2009

MDK to distribute China Sky One Medical's AMI Diagnostic Kit and Human Urinary Albumin Elisa Kit

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company developing and producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company has engaged Guangdong Mediacy Kind Medical Devices Industry Service Company ("MDK") to serve as its exclusive sales agent for the Company's AMI Diagnostic Kit and Human Urinary Albumin Elisa Kit in Southeast Asia.

1 Dec 2009

Plasma albumin levels and cardiovascular disease risk factors influenced by common genetic components

Two indicators of liver function, glutamyl transferase (GGT) and albumin (ALB) have been implicated in the pathogenesis of atherosclerosis. It is known that the variation in the plasma level of these liver related proteins is genetically influenced.

25 Nov 2009

Transplantation of human mononuclear cells exerts a deleterious effect in rats with liver cirrhosis

The use of stem cells in regenerative medicine is not always beneficial for human health, it may even be harmful according to a work done by the universities of Granada and León. Scientists have demonstrated that transplantation of human mononuclear cells isolated from umbilical cord blood exerted a deleterious effect in rats with liver cirrhosis.

12 Nov 2009

Chronic kidney disease on the rise; preventive testing is critical for diabetic patients

New data confirms the rate of chronic kidney disease is inching upward, keeping pace with the rising rates of diabetes. In late September, the U.S. Renal Data System published its 2009 Annual Data report, which shows the incidence of chronic kidney disease in the U.S. Medicare population is now 9.8%, up from 8.7% reported in last year’s data analysis.

11 Nov 2009

Abraxis BioScience reports $96.6 million net revenues for third quarter of 2009

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the third quarter ending September 30, 2009.

5 Nov 2009

FDA grants Abraxis BioScience orphan drug designation for ABRAXANE

Abraxis BioScience, Inc., a fully integrated biotechnology company, today announced that the Office of Orphan Products Development of the Food and Drug Administration (FDA) has granted orphan drug designation to the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.